Cargando…
Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study
Although the use of venous thromboembolism (VTE) chemoprophylaxis has markedly reduced VTE rates after hip fracture surgery, few studies have directly compared the efficacy of different anticoagulant agents in this setting. The purpose of this study was to compare outcomes of Lovenox, Eliquis, or Co...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746777/ https://www.ncbi.nlm.nih.gov/pubmed/36732301 http://dx.doi.org/10.5435/JAAOSGlobal-D-22-00228 |
_version_ | 1784849440132038656 |
---|---|
author | Joo, Peter Y. Modrak, Maxwell Park, Nancy Brand, Jordan Rubin, Lee E. Grauer, Jonathan N. Bernstein, Jenna A. |
author_facet | Joo, Peter Y. Modrak, Maxwell Park, Nancy Brand, Jordan Rubin, Lee E. Grauer, Jonathan N. Bernstein, Jenna A. |
author_sort | Joo, Peter Y. |
collection | PubMed |
description | Although the use of venous thromboembolism (VTE) chemoprophylaxis has markedly reduced VTE rates after hip fracture surgery, few studies have directly compared the efficacy of different anticoagulant agents in this setting. The purpose of this study was to compare outcomes of Lovenox, Eliquis, or Coumadin as VTE prophylaxis after hip fracture surgery. METHODS: The PearlDiver MHip national database was queried for patients older than 60 years undergoing first-time hip fracture surgery with no concurrent pelvic or distal femoral fractures. Prescriptions for Lovenox, Eliquis, or Coumadin were identified. Univariate and multivariate analyses of patient characteristics, 90-day incidences of VTE, adverse events, and readmissions were compared. Odds ratios (ORs) were calculated, and significance was set at P < 0.01 based on Bonferroni adjustment. RESULTS: A total of 11,384 patients were identified, with the Lovenox used for 6835 patients (60.0%), Eliquis for 1092 patients (9.6%), and Coumadin for 3457 patients (30.4%). The prevalence of 90-day VTE in the Lovenox, Eliquis, and Coumadin groups was 3.1%, 3.8%, and 5.0%, respectively (P < 0.001). Multivariate analyses adjusting for demographic and comorbidity profiles were conducted with Lovenox as the referent. Those on Eliquis had significantly lower transfusions (OR 0.52, P = 0.005), but similar rates of other outcomes including VTE (P > 0.01). Conversely, patients on Coumadin had significantly greater odds of any adverse event (OR 1.18, P < 0.001) and VTE (OR 1.58, P < 0.001). DISCUSSION: In evaluating Lovenox, Eliquis, and Coumadin as VTE chemoprophylactic agents after hip fracture surgery in anticoagulant-naïve patients, Lovenox and Eliquis had similar 90-day VTE, whereas patients on Coumadin had greater odds of 90-day VTE. Interestingly, patients on Eliquis had nearly two-fold lower odds of transfusions compared with patients on Lovenox. Although consensus on the optimal VTE prophylactic agent after hip fracture surgery does not exist, Eliquis and Lovenox may be comparable options and seem to be more effective than Coumadin. |
format | Online Article Text |
id | pubmed-9746777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-97467772022-12-16 Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study Joo, Peter Y. Modrak, Maxwell Park, Nancy Brand, Jordan Rubin, Lee E. Grauer, Jonathan N. Bernstein, Jenna A. J Am Acad Orthop Surg Glob Res Rev Research Article Although the use of venous thromboembolism (VTE) chemoprophylaxis has markedly reduced VTE rates after hip fracture surgery, few studies have directly compared the efficacy of different anticoagulant agents in this setting. The purpose of this study was to compare outcomes of Lovenox, Eliquis, or Coumadin as VTE prophylaxis after hip fracture surgery. METHODS: The PearlDiver MHip national database was queried for patients older than 60 years undergoing first-time hip fracture surgery with no concurrent pelvic or distal femoral fractures. Prescriptions for Lovenox, Eliquis, or Coumadin were identified. Univariate and multivariate analyses of patient characteristics, 90-day incidences of VTE, adverse events, and readmissions were compared. Odds ratios (ORs) were calculated, and significance was set at P < 0.01 based on Bonferroni adjustment. RESULTS: A total of 11,384 patients were identified, with the Lovenox used for 6835 patients (60.0%), Eliquis for 1092 patients (9.6%), and Coumadin for 3457 patients (30.4%). The prevalence of 90-day VTE in the Lovenox, Eliquis, and Coumadin groups was 3.1%, 3.8%, and 5.0%, respectively (P < 0.001). Multivariate analyses adjusting for demographic and comorbidity profiles were conducted with Lovenox as the referent. Those on Eliquis had significantly lower transfusions (OR 0.52, P = 0.005), but similar rates of other outcomes including VTE (P > 0.01). Conversely, patients on Coumadin had significantly greater odds of any adverse event (OR 1.18, P < 0.001) and VTE (OR 1.58, P < 0.001). DISCUSSION: In evaluating Lovenox, Eliquis, and Coumadin as VTE chemoprophylactic agents after hip fracture surgery in anticoagulant-naïve patients, Lovenox and Eliquis had similar 90-day VTE, whereas patients on Coumadin had greater odds of 90-day VTE. Interestingly, patients on Eliquis had nearly two-fold lower odds of transfusions compared with patients on Lovenox. Although consensus on the optimal VTE prophylactic agent after hip fracture surgery does not exist, Eliquis and Lovenox may be comparable options and seem to be more effective than Coumadin. Wolters Kluwer 2022-12-08 /pmc/articles/PMC9746777/ /pubmed/36732301 http://dx.doi.org/10.5435/JAAOSGlobal-D-22-00228 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Joo, Peter Y. Modrak, Maxwell Park, Nancy Brand, Jordan Rubin, Lee E. Grauer, Jonathan N. Bernstein, Jenna A. Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study |
title | Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study |
title_full | Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study |
title_fullStr | Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study |
title_full_unstemmed | Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study |
title_short | Comparing Venous Thromboembolism Prophylactic Agents After Hip Fracture Surgery: A National Database Study |
title_sort | comparing venous thromboembolism prophylactic agents after hip fracture surgery: a national database study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746777/ https://www.ncbi.nlm.nih.gov/pubmed/36732301 http://dx.doi.org/10.5435/JAAOSGlobal-D-22-00228 |
work_keys_str_mv | AT joopetery comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy AT modrakmaxwell comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy AT parknancy comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy AT brandjordan comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy AT rubinleee comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy AT grauerjonathann comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy AT bernsteinjennaa comparingvenousthromboembolismprophylacticagentsafterhipfracturesurgeryanationaldatabasestudy |